Akèy › Obèsite › New York › Rochester
Etid klinik pou Obèsite nan Rochester, NY
14 etid pou Obèsite ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 2
- Rochester Clinical Research /ID# 282484, Rochester
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Ap rekriteFaz 2
- Rochester Clinical Research, Rochester
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Ap rekriteFaz 3
- Rochester Clinical Research, LLC, Rochester
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Ap rekriteFaz 3
- Rochester Clinical Research, Rochester
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Ap rekriteFaz 3
- Rochester Clinical Research, LLC, Rochester
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Ap rekriteFaz 3
- Rochester Clinical Research, LLC, Rochester
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- Rochester Clinical Research, LLC, Rochester
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- Rochester Clinical Research, LLC, Rochester
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Ap rekriteFaz 3
- Rochester Clinical Research, Rochester
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Ap rekriteFaz 3
- Kailera Clinical Site, Rochester
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Ap rekriteFaz 3
- Rochester Clinical Research, Rochester
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Ap rekriteFaz 3
- University of Rochester, Rochester
Body Composition Related Evaluation of Airway Tone and Hyper-rEactivity Using Oscillometry
Ap rekriteEtid obsèvasyon
- University of Rochester Medical Center, Rochester
Impact of Increased Body Mass Index on Adolescent Fixed Orthodontic Treatment. A Prospective Longitudinal Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Eastman Institute for Oral Health, University of Rochester, Rochester
Etid Obèsite nan lòt vil
- Houston, TX43 etid
- Chicago, IL41 etid
- New York City, NY40 etid
- San Antonio, TX40 etid
- Washington, DC33 etid
- Orlando, FL31 etid
- Dallas, TX30 etid
- Boston, MA28 etid
- Las Vegas, NV27 etid
- Miami, FL27 etid
- Baltimore, MD25 etid
- Jacksonville, FL25 etid
Lòt etid nan Rochester
- Leksemi mieloïd egi16 etid
- Kansè poumon15 etid
- Kansè nan tete15 etid
- Kansè (tout kalite)14 etid
- Kansè Poumon ki pa ti selil13 etid
- Sipwa13 etid
- Kansè pwostat10 etid
- Myelom Miltip8 etid
- Kansè Metastatik8 etid
- Kansè pankreyas7 etid
- Distrofi myotonik7 etid
- Kansè vejik7 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.